|
1. Biologie
|
|
|
First draft of a genome-wide cancer ‘dependency map’ [Harvard Gazette]
|
|
|
|
|
|
Many
of these “dependencies,” the researchers report today in the journal
Cell, are specific to certain cancer types. However, about 10 percent of
them are common across multiple cancers, suggesting that a relatively
small number of therapies targeting these core dependencies might each
hold promise for combating several tumors.
|
|
|
|
|
|
|
|
|
3.1.1 Tabac - e-cigs
|
|
|
|
3.5 Prévention - UV
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
5. Traitements
|
|
|
Tumors caused by pluripotent stem cells can be tackled with radiation, say Stanford researchers [Stanford Medicine]
|
|
|
|
|
|
Now
cardiologists Joseph Wu, MD, PhD, Patricia Nguyen, MD, and medical
student Andrew Lee, PhD, have found that, at least in mice, it’s
possible to halt or reverse the growth of human teratoma cells arising
from the injection of pluripotent stem cells with radiation. This is a
surprise because naturally occurring teratomas are relatively resistant
to the treatment.
|
|
|
|
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
5.12.4 Immunothérapies - Essais
|
|
|
|
AstraZeneca Gets the Bad News [In the Pipeline]
|
|
|
|
|
|
Immuno-oncology
is a tremendously exciting field. But we don’t truly understand it, and
won’t for some time, and that means that things like this are going to
happen. It’ll happen again, too, to someone. Strap in.
|
|
|
|
|
|
|
|
|
AstraZeneca's Missing Takeover Defense [Bloomberg]
|
|
|
|
|
|
Blame
can't be leveled solely at Chief Executive Officer Pascal Soriot. Any
science company needs an appetite for risk, just as much as the
willingness to pull projects that look unlikely to pay off.
|
|
|
|
|
|
|
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
Don’t limit the powers of the FDA [Boston Globe]
|
|
|
|
|
|
In
other words, the nation’s oldest consumer protection agency, forged in
the wake of tragedies, for the explicit purpose of protecting patients,
would be blinded to harms linked to the products it would be charged
with reviewing for use in the general population.
|
|
|
|
|
|
|
US, EU filings for Eisai’s lenvatinib in liver cancer [Pharma Times]
|
|
|
|
|
|
Lenvatinib
is an orally administered multiple receptor tyrosine kinase (RTK)
inhibitor with a novel binding mode already on certain global markets as
a treatment for thyroid cancer, under the brand name Lenvima, and for
renal cell cancer, under the brand name Kisplyx (in the EU).
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
Overweight at 17? Your Colon Cancer Risk Rises [NY Times]
|
|
|
|
|
|
The
analysis, published in the journal Cancer, included just over one
million males and 707,212 females. Over a median follow-up of 23 years,
the investigators identified 1,977 cases of colon and rectal cancer
among the men, and 990 cases among the women.
|
|
|
|
|
|
|
Adult colorectal cancer risk tied to weight as a teen [Reuters]
|
|
|
|
|
|
Long-term
follow-up of 1.79 million Israeli men and women examined for military
service as teenagers showed that overweight and obese teens were over 50
percent more likely to develop colon or rectal cancer by middle age,
compared to normal-weight peers.
|
|
|
|
|
|
|
6.11 Patients
|
|
|
|
|
6.3 Associations/Fondations
|
|
|
|
6.7.2 Applis
|
|
|
|
6.7.3 DMP
|
|
|
|
6.9 Controverses
|
|
|
New "p < 0.005" Standard Considered Harmful [Multa Verba]
|
|
|
|
|
|
The
problem is that the vast majority of negative results are never
reported, which gives a biased picture of the state of knowledge. By
lowering the p-threshold, the file-drawer bias will be even greater,
since fewer results, with only lower p-values, are published.
|
|
|
|
|
|